FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 346:564-569 February 21, 2002 Number 8 Next

Abstract PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background A monoclonal gammopathy of undetermined significance (MGUS) occurs in up to 2 percent of persons 50 years of age or older. Reliable predictors of progression have not been identified, and information on prognosis is limited.

Methods We identified 1384 patients residing in southeastern Minnesota in whom MGUS was diagnosed at the Mayo Clinic from 1960 through 1994. The primary end point was progression to multiple myeloma or another plasma-cell cancer.

Results During 11,009 person-years of follow-up, MGUS progressed in 115 of the 1384 patients to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (relative risk of progression, 25.0, 2.4, 8.4, 46.0, 0.9, and 8.5, respectively). The overall relative risk of progression was 7.3 in these patients as compared with the white population of the Iowa Surveillance, Epidemiology, and End Results program. In 32 additional patients, the monoclonal protein concentration increased to more than 3 g per deciliter or the percentage of plasma cells in the bone marrow increased to more than 10 percent (smoldering multiple myeloma) but without progression to overt myeloma or related disorders. The cumulative probability of progression was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The initial concentration of serum monoclonal protein was a significant predictor of progression at 20 years.

Conclusions The risk of progression of MGUS to multiple myeloma or related disorders is about 1 percent per year.

In previous, smaller series of patients with MGUS who were followed for 5 to 10 years, malignant transformation occurred in 7 to 19 percent.^8,9,10 However, the reliability of these results is limited by small numbers of patients or short follow-up. In addition, most reports are from tertiary medical centers, where the results may be distorted by selective referral of patients at greater risk for adverse outcomes. We evaluated the prognosis and predictors of outcome in a large cohort of patients with MGUS who were identified in a well-defined geographic area and followed for up to 35 years.

Methods

Patients

After approval by the institutional review board of the Mayo Clinic, we identified 1395 persons with MGUS who resided in the 11 counties of southeastern Minnesota and who had serum monoclonal protein at a concentration of 3 g per deciliter or less (thus, patients with smoldering multiple myeloma, characterized by a monoclonal protein value of more than 3 g per deciliter or more than 10 percent plasma cells in the bone marrow, were excluded). If bone marrow examination was performed, the plasma-cell content had to be 10 percent or less. Bone marrow examination is not necessary unless the monoclonal protein value is more than 2 g per deciliter or the patient has unexplained anemia, renal insufficiency, hypercalcemia, or bone pain. The patients were evaluated at the Mayo Clinic from January 1, 1960, through December 31, 1994; 11 declined to authorize review of their medical records for research.¹¹ Of the remaining 1384 patients, 514 (37 percent) resided in Olmsted County (1980 population, 92,006) and the remaining 870 resided in the other counties of southeastern Minnesota (1980 population, 312,559). The medical-records-linkage system of the Rochester Epidemiology Project¹² makes possible complete case ascertainment among Olmsted County residents.

Follow-up included review of each patient's inpatient and outpatient medical records at the Mayo Clinic and review of death certificates for all who died. Monoclonal proteins were identified by cellulose acetate or agarose-gel electrophoresis¹³; if there was an abnormal band or equivocal pattern, immunoelectrophoresis or immunofixation was performed. Patients were advised to undergo serum protein electrophoresis annually and were contacted if they did not.

End Points

The primary end point of the study was progression to multiple myeloma or other B-cell or lymphoid cancer. Analyses were performed with respect to progression to multiple myeloma or related cancer. In addition, patients were identified who had an increase in the proportion of plasma cells in bone marrow to more than 10 percent or an increase in the serum monoclonal protein value to more than 3 g per deciliter, but with no other features of symptomatic multiple myeloma. The end points with respect to progression were calculated in terms of both the cumulative probability and the cumulative incidence of progression. The cumulative probability was calculated with a Kaplan–Meier estimate¹⁴ in which data on patients who died were censored; curves were compared by the log-rank test.¹⁵ The effects of potential risk factors on progression rates were examined in a Cox proportional-hazards model.¹⁶ The cumulative-incidence curve, however, explicitly accounted for other causes of death and was computed by the method of Gooley et al.¹⁷

The risk of progression to each disease we studied, relative to the risk in the general population, was determined by applying age- and sex-specific incidence rates for these conditions in the white cohort from the Iowa Surveillance, Epidemiology, and End Results (SEER) program¹⁸ to the age-, sex-, and calendar-year–specific number of person-years of follow-up in our study cohort. The confidence intervals for relative risks are based on a Poisson approach.¹⁹

Statistical Analysis

Demographic and base-line laboratory data were compared for consistency among subpopulations (residents vs. nonresidents of Olmsted County) with ² tests for nominal variables and t-tests for ordinal variables. All statistical tests were two-sided. Analyses were performed with SAS software (version 6.12, SAS Institute, Cary, N.C.) and S-Plus (version 3.4, Insightful, Seattle).

Results

Base-Line Characteristics

Of the 1384 patients with a serum monoclonal protein concentration of 3 g per deciliter or less, 753 (54 percent) were men and 631 (46 percent) were women. The median age at the diagnosis of MGUS was 72 years. Only 24 patients (2 percent) were younger than 40 years at diagnosis, whereas 810 (59 percent) were 70 years of age or older. There were no statistically or clinically significant differences between residents and nonresidents of Olmsted County, except that Olmsted County residents were slightly older (median age, 73 years, vs. 72 years among nonresidents; P=0.04) and had a higher concentration of monoclonal protein (median, 1.3 vs. 1.2 g per deciliter; P=0.01). Therefore, these groups were combined for analysis. The overall median value for serum monoclonal protein at diagnosis ranged from unmeasurable (visible as a small band on electrophoresis but not quantifiable by densitometry) to 3.0 g per deciliter (Figure 1). Of the monoclonal protein found in these patients, 70 percent was IgG, 12 percent IgA, and 15 percent IgM; a biclonal gammopathy was found in 3 percent. The light chain was kappa in 61 percent and lambda in 39 percent. The concentrations of uninvolved (normal, polyclonal, or background) immunoglobulins were reduced in 38 percent of 840 patients whose immunoglobulin concentrations were determined quantitatively. The median concentrations of the reduced immunoglobulins were 40 mg per deciliter for IgA, 50 mg per deciliter for IgM, and 580 mg per deciliter for IgG. Electrophoresis, immunoelectrophoresis, and immunofixation were performed on urine from 418 of the patients with MGUS; 21 percent had a monoclonal kappa light chain, 10 percent had a lambda light chain, and 69 percent were negative for monoclonal light chain. Only 17 percent had a urinary monoclonal protein value greater than 150 mg per 24 hours.

View larger version (6K): [in this window] [in a new window]   Figure 1. Initial Monoclonal Protein Values in 1384 Residents of Southeastern Minnesota in Whom Monoclonal Gammopathy of Undetermined Significance Was Diagnosed from 1960 through 1994.

 
The bone marrow of 160 patients (12 percent) was examined when the monoclonal protein was first detected. The median percentage of bone marrow made up of plasma cells was 3 percent (range, 0 to 10 percent). The initial hemoglobin values for all patients ranged from 5.7 to 18.9 g per deciliter; the value was less than 10.0 g per deciliter in 7 percent and 12.0 g per deciliter or less in 23 percent. In each case, anemia was due to causes other than plasma-cell proliferation, such as iron deficiency, renal insufficiency, or myelodysplasia. The serum creatinine value was more than 2 mg per deciliter (177 µmol per liter) in 6 percent of patients, and the elevation was attributable to other causes (diabetes, hypertension, or glomerulonephropathy).

Outcome

The 1384 patients were followed for 11,009 person-years (median, 15.4 years; range, 0 to 35 years), during which 963 (70 percent) died. During follow-up, multiple myeloma, lymphoma with an IgM serum monoclonal protein, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma developed in 115 patients (8 percent) (Table 1). The cumulative probability of progression to one of those disorders was 10 percent at 10 years, 21 percent at 20 years, and 26 percent at 25 years (Figure 2). The overall risk of progression was about 1 percent per year, and patients were at risk for progression even after 25 years or more of stable MGUS. We also identified 32 patients in whom the monoclonal protein value increased to more than 3 g per deciliter or the percentage of bone marrow plasma cells increased to more than 10 percent, but in whom multiple myeloma did not develop. The cumulative probability of progression to multiple myeloma or a related disorder and an increase in monoclonal protein to more than 3 g per deciliter or in bone marrow plasma cells to more than 10 percent (Figure 2) was 12 percent at 10 years, 25 percent at 20 years, and 30 percent at 25 years. The rates of death due to other diseases, which included cardiovascular and cerebrovascular diseases and non–plasma-cell cancers, were 53 percent at 10 years, 72 percent at 20 years, and 76 percent at 25 years, as compared with 6 percent at 10 years, 10 percent at 20 years, and 11 percent at 25 years for death due to plasma-cell cancers. Patients with MGUS had shorter median survival than expected for Minnesota residents of matched age and sex (8.1 vs. 11.8 years, P<0.001). The risk of death at 10 years for patients with MGUS was 6 percent from plasma-cell disorders and 53 percent from non–plasma-cell disorders; the overall 10-year death rate expected for age- and sex-matched Minnesota residents was 43 percent. At 20 years, the death rates for patients with MGUS were 10 percent from plasma-cell disorders and 72 percent from non–plasma-cell disorders, and the expected death rate for Minnesota residents was 73 percent.

View this table: [in this window] [in a new window]   Table 1. Risk of Progression among 1384 Residents of Southeastern Minnesota in Whom Monoclonal Gammopathy of Undetermined Significance was Diagnosed in 1960 through 1994.

 

View larger version (13K): [in this window] [in a new window]   Figure 2. Probability of Progression among 1384 Residents of Southeastern Minnesota in Whom Monoclonal Gammopathy of Undetermined Significance (MGUS) Was Diagnosed from 1960 through 1994. The top curve shows the probability of progression to a plasma-cell cancer (115 patients) or of an increase in the monoclonal protein concentration to more than 3 g per deciliter or the proportion of plasma cells in bone marrow to more than 10 percent (32 patients). The bottom curve shows only the probability of progression of MGUS to multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, or plasmacytoma (115 patients). The bars show 95 percent confidence intervals.

 
The number of patients with progression to a plasma-cell neoplasm or related disorder (115 patients) was more than seven times that expected on the basis of incidence rates for those conditions in the general population (Table 1). The risk of disease was increased by a factor of 25.0 for multiple myeloma, 46.0 for macroglobulinemia, and 8.4 for primary amyloidosis. The risk of lymphoma was only moderately increased, with a relative risk of 2.4, but this value is an underestimate because only lymphomas associated with an IgM protein were counted in the observed number, whereas the incidence rates for all lymphomas were used to calculate the expected number (Table 1). The risk of chronic lymphocytic leukemia was only slightly increased (Table 1) when all cases were included.

The 75 patients in whom multiple myeloma developed accounted for 65 percent of the 115 patients who had progression to a plasma-cell cancer. Three of these patients also had primary systemic amyloidosis. Multiple myeloma was diagnosed more than 10 years after the detection of the monoclonal protein in 24 of the 75 patients (32 percent) and after 20 years of follow-up in 5 patients (7 percent). The pattern of development of multiple myeloma among patients with MGUS was variable (Table 2).

View this table: [in this window] [in a new window]   Table 2. Patterns of Increase in Monoclonal Protein among 1384 Residents of Southeastern Minnesota in Whom Monoclonal Gammopathy Was Diagnosed in 1960 through 1994.

 
The monoclonal protein disappeared during follow-up in 66 patients (5 percent). All these patients had low initial concentrations of monoclonal protein; only 17 had a value greater than 0.5 g per deciliter at diagnosis. However, treatment of patients who had progression to lymphoma or multiple myeloma or who had other disorders, such as idiopathic thrombocytopenic purpura and vasculitis unrelated to the monoclonal gammopathy, caused the disappearance of the monoclonal protein in 39 cases. The monoclonal protein disappeared without a known cause in 27 patients (2 percent). Only 6 of these 27 patients (0.4 percent of all patients) had a discrete spike, or peak, on the densitometer tracing that could be measured on the initial electrophoresis (median, 1.2 g per deciliter), whereas the remaining 21 had a small monoclonal protein that could not be measured by the densitometer. In 19 additional patients, the results of immunofixation or immunoelectrophoresis were initially thought to represent a monoclonal protein, but subsequent studies showed no evidence of monoclonal protein, suggesting that it was not present initially. Nevertheless, patients with a small monoclonal protein (0.5 g per deciliter or less) had a 14 percent risk of progression at 20 years.

Risk Factors for Progression

Among the base-line factors evaluated with respect to predicting the progression of monoclonal gammopathy to multiple myeloma or related plasma-cell disorders (115 patients) (age; sex; hepatosplenomegaly; values for hemoglobin, serum creatinine, and serum albumin; concentration of serum monoclonal protein; type of serum monoclonal protein [IgG, IgA, or IgM]; presence, type, and amount of monoclonal urinary light chain; number of bone marrow plasma cells; and reduction in uninvolved immunoglobulins), only the concentration and type of monoclonal protein were independent predictors of progression. The presence of a monoclonal urinary light chain (kappa or lambda) or a reduction in one or more uninvolved immunoglobulins was not a risk factor for progression (Table 3). Patients with IgM or IgA monoclonal protein had an increased risk of progression to disease, as compared with patients who had IgG monoclonal protein (P=0.001). However, the initial concentration of the serum monoclonal protein was the most important risk factor for progression to plasma-cell cancer. The relative risk of progression was directly related to the concentration of monoclonal protein in the serum at the time of diagnosis of MGUS.

View this table: [in this window] [in a new window]   Table 3. Rates of Progression to Multiple Myeloma or a Related Neoplasm among 1384 Residents of Southeastern Minnesota in Whom Monoclonal Gammopathy of Undetermined Significance Was Diagnosed in 1960 through 1994, According to the Type of Urinary Light Chain or Reduction of Uninvolved Immunoglobulins.

 
The risk of progression to multiple myeloma or a related cancer 10 years after the diagnosis of MGUS was 6 percent for an initial monoclonal protein value of 0.5 g per deciliter or less, 7 percent for a value of 1 g per deciliter, 11 percent for 1.5 g per deciliter, 20 percent for 2 g per deciliter, 24 percent for 2.5 g per deciliter, and 34 percent for 3.0 g per deciliter (P<0.001).

The risk of progression to multiple myeloma or related disorders (in 115 patients) at 20 years with an initial monoclonal protein value of 1.5 g per deciliter was 1.9 times the risk of progression with an initial value of 0.5 g per deciliter or less; the risk of progression with a monoclonal protein value of 2.5 g per deciliter was 4.6 times the risk of progression with an initial value of 0.5 g per deciliter or less. The risk of progression at 20 years was 14 percent for an initial monoclonal protein value of 0.5 g per deciliter or less, 25 percent for an initial monoclonal protein value of 1.5 g per deciliter, 41 percent for an initial monoclonal protein value of 2.0 g per deciliter, 49 percent for an initial monoclonal protein value of 2.5 g per deciliter, and 64 percent for an initial monoclonal protein value of 3.0 g per deciliter.

Discussion

Patients with MGUS are at increased risk for progression to multiple myeloma or a related plasma-cell cancer. In this study of 1384 patients with MGUS, with a total of 11,009 person-years of follow-up, we identified the predictors and patterns of progression, showed that spontaneous resolution of MGUS can occur, and compared the survival of patients with MGUS with that in an age- and sex-matched control population.

We defined MGUS by the presence of serum monoclonal protein at a concentration of 3 g per deciliter or less, no or only moderate amounts of monoclonal light chains in the urine, and the absence of lytic bone lesions, anemia, hypercalcemia, or renal insufficiency related to the monoclonal protein. If bone marrow is examined, the marrow must contain less than 10 percent plasma cells. We do not believe that a bone marrow examination or a bone survey is necessary for a patient with a low concentration of monoclonal protein (less than 2 g per deciliter) unless other features suggest the possibility of multiple myeloma.

Formerly, if the monoclonal protein value in a patient with MGUS remained stable for three to five years, the process was believed to be benign, and additional follow-up was not considered to be required. This study and our previous experience⁶ demonstrate an average risk of the development of a serious disease of almost 1 percent each year. In the current study, we found a relative risk of 7.3 for multiple myeloma, IgM lymphoma, primary amyloidosis, macroglobulinemia, chronic lymphocytic leukemia, and plasmacytoma in the patients with MGUS as compared with white subjects in the Iowa SEER registry from 1973 to 1997.¹⁸ This increased risk was found in all age groups and throughout all time intervals. The relative risk of chronic lymphocytic leukemia was only slightly elevated.

It is unusual for a serum monoclonal protein to disappear during long-term follow-up. Many patients (39) in whom the monoclonal protein disappeared underwent treatment for myeloma or lymphoma or for unrelated disorders, such as idiopathic thrombocytopenic purpura or vasculitis. Only six patients (0.4 percent) had a measurable monoclonal protein that later disappeared without apparent cause.

Distinguishing the patient with a stable monoclonal gammopathy from one in whom multiple myeloma or a related disorder will eventually develop is difficult when MGUS is initially recognized. In a comparison of patients with various monoclonal protein values, in which 0.5 g per deciliter or less was used as a reference value, we found that the initial concentration of monoclonal protein was a statistically significant predictor of progression to multiple myeloma. The risk of progression was also greater among patients with IgA or IgM monoclonal gammopathy than in those with an IgG gammopathy.

The concentrations of normal polyclonal or background immunoglobulins are reduced in 93 percent of patients with multiple myeloma²¹ but are thought to be normal in those with benign monoclonal gammopathy. However, we found reduced concentrations of uninvolved immunoglobulins in 29 percent of our original cohort of 241 patients with MGUS⁶ and in 38 percent of the 840 patients in the current group in whom immunoglobulins were measured. Such a reduction, however, did not identify patients in whom progression subsequently developed.

Karyotyping is of no value in determining the risk of progression, because cells in metaphase are rare in MGUS. The early results of fluorescence in situ hybridization are abnormal in more than half of patients with MGUS, but the prognostic significance of these findings is under investigation.²²

In the 32 patients in whom the monoclonal protein value increased to more than 3 g per deciliter or the percentage of plasma cells in bone marrow increased to more than 10 percent without overt cancer, multiple myeloma or a related disorder would probably have developed had they been followed for a sufficient time. However, it is important to keep in mind that patients with MGUS are more likely to die of an unrelated disease than to have progression to a malignant plasma-cell disorder. Indeed, the actual risk of death from multiple myeloma and related disorders is overstated when one ignores the greater risk of death from other causes in these mostly elderly patients (data not shown).

Although we do not have evidence that monitoring improves survival, we believe that patients with MGUS should be monitored annually with serum protein electrophoresis to detect multiple myeloma before complications such as renal failure or pathologic fractures occur. Averting these events would improve the patient's quality of life and reduce the cost of long-term dialysis or surgical intervention for skeletal complications.

Supported in part by a research grant (CA62242) from the National Cancer Institute.

Source Information

From the Division of Hematology and Internal Medicine (R.A.K., S.V.R.), the Section of Biostatistics (T.M.T., J.R.O., D.R.L., M.F.P.), and the Section of Clinical Epidemiology (L.J.M.), Mayo Clinic, Rochester, Minn.

Address reprint requests to Dr. Kyle at the Mayo Clinic, 200 First St. SW, Rochester, MN 55905, or at kyle.robert{at}mayo.edu.

References

1. Hällén J. Frequency of "abnormal" serum globulins (M-components) in the aged. Acta Med Scand 1963;173:737-744. [Web of Science][Medline]
2. Hällén J. Discrete gammaglobulin (M-) components in serum: clinical study of 150 subjects without myelomatosis. Acta Med Scand Suppl 1966;462:1-127. [Medline]
3. Axelsson U, Bachmann R, Hällén J. Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Med Scand 1966;179:235-247. [Web of Science][Medline]
4. Kyle RA, Finkelstein S, Elveback LR, Kurland LT. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. Blood 1972;40:719-724. [Free Full Text]
5. Saleun JP, Vicariot M, Deroff P, Morin JF. Monoclonal gammopathies in the adult population of Finistère, France. J Clin Pathol 1982;35:63-68. [Free Full Text]
6. Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med 1978;64:814-826. [CrossRef][Web of Science][Medline]
7. Kyle RA. "Benign" monoclonal gammopathy -- after 20 to 35 years of follow-up. Mayo Clin Proc 1993;68:26-36. [Web of Science][Medline]
8. Bladé J, López-Guillermo A, Rozman C, et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. Br J Haematol 1992;81:391-394. [Web of Science][Medline]
9. van de Poel MH, Coebergh JW, Hillen HF. Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in southeastern Netherlands. Br J Haematol 1995;91:121-125. [Web of Science][Medline]
10. Baldini L, Guffanti A, Cesana BM, et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood 1996;87:912-918. [Free Full Text]
11. Melton LJ III. The threat to medical-records research. N Engl J Med 1997;337:1466-1470. [Free Full Text]
12. Melton LJ III. History of the Rochester Epidemiology Project. Mayo Clin Proc 1996;71:266-274. [Abstract]
13. Kyle RA, Katzmann JA. Immunochemical characterization of immunoglobulins. In: Rose NR, Conway de Macario E, Folds JD, Lane HC, Nakamura RM, eds. Manual of clinical laboratory immunology. 5th ed. Washington, D.C.: ASM Press, 1997:156-76.
14. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
15. Peto R, Peto J. Asymptotically efficient rank invariant test procedures. J R Stat Soc [A] 1972;135:185-206.
16. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220.
17. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706. [CrossRef][Web of Science][Medline]
18. Surveillance, Epidemiology, and End Results (SEER) Program public-use data (1973-1998). Bethesda, Md.: National Cancer Institute, Cancer Statistics Branch, April 2001.
19. Berry G. The analysis of mortality by the subject-years method. Biometrics 1983;39:173-184. [CrossRef][Web of Science][Medline]
20. Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood 1992;79:1817-1822. [Free Full Text]
21. Kyle RA, Greipp PR, Witzig TE, et al. An analysis of 1027 newly diagnosed cases of multiple myeloma. Blood 1999;94:Suppl 1:537a-537a.abstract 
22. Fonseca R, Aguayo P, Ahmann GJ, et al. Translocations at 14q32 are common in patients with the monoclonal gammopathy of undetermined significance (MGUS) and involve several partner chromosomes. Blood 1999;94:Suppl 1:663a-663a.abstract 

Abstract PDF PDA Full Text PowerPoint Slide Set Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Related Letters:

Monoclonal Gammopathy of Undetermined Significance
Fiegl M., Greil R., Montoto S., Bladé J., Montserrat E., Jokl D. H.-K., Kyle R. A., Rajkumar S. V., Melton J. III
Extract | Full Text | PDF  
N Engl J Med 2002; 346:2087-2088, Jun 27, 2002. Correspondence

This article has been cited by other articles:

• Blotta, S., Tassone, P., Prabhala, R. H., Tagliaferri, P., Cervi, D., Amin, S., Jakubikova, J., Tai, Y.-T., Podar, K., Mitsiades, C. S., Zullo, A., Franco, B., Anderson, K. C., Munshi, N. C. (2009). Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood 114: 3276-3284 [Abstract] [Full Text]  
• Rajkumar, S. V. (2009). Prevention of Progression in Monoclonal Gammopathy of Undetermined Significance. Clin. Cancer Res. 15: 5606-5608 [Abstract] [Full Text]  
• Landgren, O., Kyle, R. A., Rajkumar, V. (2009). Response: Multiple myeloma is universally preceded by a prolonged premalignant stage: novel clinical insights and future directions. Blood 114: 2356-2357 [Full Text]  
• Anguiano, A., Tuchman, S. A., Acharya, C., Salter, K., Gasparetto, C., Zhan, F., Dhodapkar, M., Nevins, J., Barlogie, B., Shaughnessy, J. D. Jr, Potti, A. (2009). Gene Expression Profiles of Tumor Biology Provide a Novel Approach to Prognosis and May Guide the Selection of Therapeutic Targets in Multiple Myeloma. JCO 27: 4197-4203 [Abstract] [Full Text]  
• Ria, R., Todoerti, K., Berardi, S., Coluccia, A. M. L., De Luisi, A., Mattioli, M., Ronchetti, D., Morabito, F., Guarini, A., Petrucci, M. T., Dammacco, F., Ribatti, D., Neri, A., Vacca, A. (2009). Gene Expression Profiling of Bone Marrow Endothelial Cells in Patients with Multiple Myeloma. Clin. Cancer Res. 15: 5369-5378 [Abstract] [Full Text]  
• Bauerle, T., Hillengass, J., Fechtner, K., Zechmann, C. M., Grenacher, L., Moehler, T. M., Christiane, H., Barbara, W.-G., Neben, K., Kauczor, H.-U., Goldschmidt, H., Delorme, S. (2009). Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance: Importance of Whole-Body versus Spinal MR Imaging. Radiology 252: 477-485 [Abstract] [Full Text]  
• Bida, J. P., Kyle, R. A., Therneau, T. M., Melton, L. J. III, Plevak, M. F., Larson, D. R., Dispenzieri, A., Katzmann, J. A., Rajkumar, S. V. (2009). Disease Associations With Monoclonal Gammopathy of Undetermined Significance: A Population-Based Study of 17,398 Patients. Mayo Clin Proc. 84: 685-693 [Abstract] [Full Text]  
• Katzmann, J. A., Kyle, R. A., Benson, J., Larson, D. R., Snyder, M. R., Lust, J. A., Rajkumar, S. V., Dispenzieri, A. (2009). Screening Panels for Detection of Monoclonal Gammopathies. Clin. Chem. 55: 1517-1522 [Abstract] [Full Text]  
• Kristinsson, S. Y., Goldin, L. R., Bjorkholm, M., Turesson, I., Landgren, O. (2009). Risk of solid tumors and myeloid hematological malignancies among first-degree relatives of patients with monoclonal gammopathy of undetermined significance. haematol 94: 1179-1181 [Full Text]  
• Vachon, C. M., Kyle, R. A., Therneau, T. M., Foreman, B. J., Larson, D. R., Colby, C. L., Phelps, T. K., Dispenzieri, A., Kumar, S. K., Katzmann, J. A., Rajkumar, S. V. (2009). Increased risk of monoclonal gammopathy in first-degree relatives of patients with multiple myeloma or monoclonal gammopathy of undetermined significance. Blood 114: 785-790 [Abstract] [Full Text]  
• Rossi, F., Petrucci, M. T., Guffanti, A., Marcheselli, L., Rossi, D., Callea, V., Vincenzo, F., De Muro, M., Baraldi, A., Villani, O., Musto, P., Bacigalupo, A., Gaidano, G., Avvisati, G., Goldaniga, M., DePaoli, L., Baldini, L. (2009). Proposal and Validation of Prognostic Scoring Systems for IgG and IgA Monoclonal Gammopathies of Undetermined Significance. Clin. Cancer Res. 15: 4439-4445 [Abstract] [Full Text]  
• Landgren, O., Kyle, R. A., Hoppin, J. A., Beane Freeman, L. E., Cerhan, J. R., Katzmann, J. A., Rajkumar, S. V., Alavanja, M. C. (2009). Pesticide exposure and risk of monoclonal gammopathy of undetermined significance in the Agricultural Health Study. Blood 113: 6386-6391 [Abstract] [Full Text]  
• Blade, J., Rosinol, L., Cibeira, M. T. (2009). Are all myelomas preceded by MGUS?. Blood 113: 5370-5370 [Full Text]  
• Landgren, O., Kyle, R. A., Pfeiffer, R. M., Katzmann, J. A., Caporaso, N. E., Hayes, R. B., Dispenzieri, A., Kumar, S., Clark, R. J., Baris, D., Hoover, R., Rajkumar, S. V. (2009). Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113: 5412-5417 [Abstract] [Full Text]  
• Weiss, B. M., Abadie, J., Verma, P., Howard, R. S., Kuehl, W. M. (2009). A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113: 5418-5422 [Abstract] [Full Text]  
• Hillengass, J., Zechmann, C., Bauerle, T., Wagner-Gund, B., Heiss, C., Benner, A., Ho, A., Neben, K., Hose, D., Kauczor, H.-U., Goldschmidt, H., Delorme, S., Moehler, T. (2009). Dynamic Contrast-Enhanced Magnetic Resonance Imaging Identifies a Subgroup of Patients with Asymptomatic Monoclonal Plasma Cell Disease and Pathologic Microcirculation. Clin. Cancer Res. 15: 3118-3125 [Abstract] [Full Text]  
• Iwanaga, M., Tagawa, M., Tsukasaki, K., Matsuo, T., Yokota, K.-i., Miyazaki, Y., Fukushima, T., Hata, T., Imaizumi, Y., Imanishi, D., Taguchi, J., Momita, S., Kamihira, S., Tomonaga, M. (2009). Relationship between monoclonal gammopathy of undetermined significance and radiation exposure in Nagasaki atomic bomb survivors. Blood 113: 1639-1650 [Abstract] [Full Text]  
• Vogt, R. F. Jr., Kyle, R. A. (2009). The Secret Lives of Monoclonal B Cells. NEJM 360: 722-723 [Full Text]  
• Pinzone, J. J., Hall, B. M., Thudi, N. K., Vonau, M., Qiang, Y.-W., Rosol, T. J., Shaughnessy, J. D. Jr (2009). The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113: 517-525 [Abstract] [Full Text]  
• Piehler, A. P., Gulbrandsen, N., Kierulf, P., Urdal, P. (2008). Quantitation of Serum Free Light Chains in Combination with Protein Electrophoresis and Clinical Information for Diagnosing Multiple Myeloma in a General Hospital Population. Clin. Chem. 54: 1823-1830 [Abstract] [Full Text]  
• Barlogie, B., van Rhee, F., Shaughnessy, J. D. Jr, Epstein, J., Yaccoby, S., Pineda-Roman, M., Hollmig, K., Alsayed, Y., Hoering, A., Szymonifka, J., Anaissie, E., Petty, N., Kumar, N. S., Srivastava, G., Jenkins, B., Crowley, J., Zeldis, J. B. (2008). Seven-year median time to progression with thalidomide for smoldering myeloma: partial response identifies subset requiring earlier salvage therapy for symptomatic disease. Blood 112: 3122-3125 [Abstract] [Full Text]  
• Caligaris-Cappio, F., Ghia, P. (2008). Novel Insights in Chronic Lymphocytic Leukemia: Are We Getting Closer to Understanding the Pathogenesis of the Disease?. JCO 26: 4497-4503 [Abstract] [Full Text]  
• Rawstron, A. C., Bennett, F. L., O'Connor, S. J.M., Kwok, M., Fenton, J. A.L., Plummer, M., de Tute, R., Owen, R. G., Richards, S. J., Jack, A. S., Hillmen, P. (2008). Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia. NEJM 359: 575-583 [Abstract] [Full Text]  
• Sheldon, J. (2008). Free light chains: author's response. Ann Clin Biochem 45: 445-446 [Full Text]  
• Kyle, R. A., Rajkumar, S. V. (2008). Multiple myeloma. Blood 111: 2962-2972 [Abstract] [Full Text]  
• Sack, F.-U., Kristen, A., Goldschmidt, H., Schnabel, P. A., Dengler, T., Koch, A., Karck, M. (2008). Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur. J. Cardiothorac. Surg. 33: 257-262 [Abstract] [Full Text]  
• Jinushi, M., Vanneman, M., Munshi, N. C., Tai, Y.-T., Prabhala, R. H., Ritz, J., Neuberg, D., Anderson, K. C., Carrasco, D. R., Dranoff, G. (2008). MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc. Natl. Acad. Sci. USA 105: 1285-1290 [Abstract] [Full Text]  
• Dispenzieri, A., Kyle, R. A., Katzmann, J. A., Therneau, T. M., Larson, D., Benson, J., Clark, R. J., Melton, L. J. III, Gertz, M. A., Kumar, S. K., Fonseca, R., Jelinek, D. F., Rajkumar, S. V. (2008). Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 111: 785-789 [Abstract] [Full Text]  
• Sackmann, F., Pavlovsky, M. A., Corrado, C., Pizzolato, M., Alejandre, M., Pavlovsky, S. (2008). Prognostic factors in monoclonal gammopathy of undetermined significance. haematol 93: 153-154 [Abstract] [Full Text]  
• Martin-Ayuso, M., Almeida, J., Perez-Andres, M., Cuello, R., Galende, J., Gonzalez-Fraile, M. I., Martin-Nunez, G., Ortega, F., Rodriguez, M. J., San Miguel, J. F., Orfao, A. (2008). Peripheral Blood Dendritic Cell Subsets from Patients with Monoclonal Gammopathies Show an Abnormal Distribution and Are Functionally Impaired. The Oncologist 13: 82-92 [Abstract] [Full Text]  
• Landgren, O., Katzmann, J. A., Hsing, A. W., Pfeiffer, R. M., Kyle, R. A., Yeboah, E. D., Biritwum, R. B., Tettey, Y., Adjei, A. A., Larson, D. R., Dispenzieri, A., Melton, L. J. III, Goldin, L. R., McMaster, M. L., Caporaso, N. E., Rajkumar, S. V. (2007). Prevalence of Monoclonal Gammopathy of Undetermined Significance Among Men in Ghana. Mayo Clin Proc. 82: 1468-1473 [Abstract] [Full Text]  
• Iwanaga, M., Tagawa, M., Tsukasaki, K., Kamihira, S., Tomonaga, M. (2007). Prevalence of Monoclonal Gammopathy of Undetermined Significance: Study of 52,802 Persons in Nagasaki City, Japan. Mayo Clin Proc. 82: 1474-1479 [Abstract] [Full Text]  
• Brousseau, M., Leleu, X., Gerard, J., Gastinne, T., Godon, A., Genevieve, F., Dib, M., Lai, J.-L., Facon, T., Zandecki, M., for the Intergroupe Francophone du Myelome, (2007). Hyperdiploidy Is a Common Finding in Monoclonal Gammopathy of Undetermined Significance and Monosomy 13 Is Restricted to These Hyperdiploid Patients. Clin. Cancer Res. 13: 6026-6031 [Abstract] [Full Text]  
• Perez-Persona, E., Vidriales, M.-B., Mateo, G., Garcia-Sanz, R., Mateos, M.-V., de Coca, A. G., Galende, J., Martin-Nunez, G., Alonso, J. M., de las Heras, N., Hernandez, J. M., Martin, A., Lopez-Berges, C., Orfao, A., San Miguel, J. F. (2007). New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110: 2586-2592 [Abstract] [Full Text]  
• Steingrimsdottir, H., Haraldsdottir, V., Olafsson, I., Gudnason, V., Ogmundsdottir, H. M. (2007). Monoclonal gammopathy: natural history studied with a retrospective approach. haematol 92: 1131-1134 [Abstract] [Full Text]  
• Kyle, R. A., Remstein, E. D., Therneau, T. M., Dispenzieri, A., Kurtin, P. J., Hodnefield, J. M., Larson, D. R., Plevak, M. F., Jelinek, D. F., Fonseca, R., Melton, L. J. III, Rajkumar, S. V. (2007). Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma. NEJM 356: 2582-2590 [Abstract] [Full Text]  
• Vijay, A., Gertz, M. A. (2007). Waldenstrom macroglobulinemia. Blood 109: 5096-5103 [Abstract] [Full Text]  
• Landgren, O., Turesson, I., Gridley, G., Caporaso, N. E. (2007). Risk of Malignant Disease Among 1525 Adult Male US Veterans With Gaucher Disease. Arch Intern Med 167: 1189-1194 [Abstract] [Full Text]  
• Austin, S., Cohen, H., Losseff, N. (2007). Haematology and neurology. J. Neurol. Neurosurg. Psychiatry 78: 334-341 [Abstract] [Full Text]  
• Rosinol, L., Cibeira, M. T., Montoto, S., Rozman, M., Esteve, J., Filella, X., Blade, J. (2007). Monoclonal Gammopathy of Undetermined Significance: Predictors of Malignant Transformation and Recognition of an Evolving Type Characterized by a Progressive Increase in M Protein Size. Mayo Clin Proc. 82: 428-434 [Abstract] [Full Text]  
• Cook, L., Macdonald, D. H C (2007). Management of paraproteinaemia. Postgrad. Med. J. 83: 217-223 [Abstract] [Full Text]  
• Condomines, M., Hose, D., Raynaud, P., Hundemer, M., De Vos, J., Baudard, M., Moehler, T., Pantesco, V., Moos, M., Schved, J.-F., Rossi, J.-F., Reme, T., Goldschmidt, H., Klein, B. (2007). Cancer/Testis Genes in Multiple Myeloma: Expression Patterns and Prognosis Value Determined by Microarray Analysis. J. Immunol. 178: 3307-3315 [Abstract] [Full Text]  
• Landgren, O., Rapkin, J. S., Caporaso, N. E., Mellemkjaer, L., Gridley, G., Goldin, L. R., Engels, E. A. (2007). Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 109: 2198-2201 [Abstract] [Full Text]  
• Zhan, F., Barlogie, B., Arzoumanian, V., Huang, Y., Williams, D. R., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Zangari, M., Dhodapkar, M., Shaughnessy, J. D. Jr (2007). Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. Blood 109: 1692-1700 [Abstract] [Full Text]  
• Ramos, R., Poveda, R., Sarra, J., Domingo, A., Carreras, L., Grinyo, J. M. (2007). Renal involvement in non-malignant IgM gammopathy. Nephrol Dial Transplant 22: 627-630 [Full Text]  
• Chim, C.-S., Liang, R., Leung, M.-H., Kwong, Y.-L. (2007). Aberrant gene methylation implicated in the progression of monoclonal gammopathy of undetermined significance to multiple myeloma. J. Clin. Pathol. 60: 104-106 [Abstract] [Full Text]  
• Richardson, P. G., Hideshima, T., Anderson, K. C. (2007). Plasma cell dyscrasias. ASH-SAP 2007: 298-327 [Full Text]  
• Blade, J. (2006). Monoclonal Gammopathy of Undetermined Significance. NEJM 355: 2765-2770 [Full Text]  
• Zhan, F., Huang, Y., Colla, S., Stewart, J. P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B., Shaughnessy, J. D. Jr (2006). The molecular classification of multiple myeloma. Blood 108: 2020-2028 [Abstract] [Full Text]  
• Rajkumar, S. V., Dispenzieri, A., Kyle, R. A. (2006). Monoclonal Gammopathy of Undetermined Significance, Waldenstrom Macroglobulinemia, AL Amyloidosis, and Related Plasma Cell Disorders: Diagnosis and Treatment. Mayo Clin Proc. 81: 693-703 [Abstract] [Full Text]  
• Schmid, J. M. P., Junge, S. A., Hossle, J. P., Schneider, E. M., Roosnek, E., Seger, R. A., Gungor, T. (2006). Transient Hemophagocytosis With Deficient Cellular Cytotoxicity, Monoclonal Immunoglobulin M Gammopathy, Increased T-Cell Numbers, and Hypomorphic NEMO Mutation. Pediatrics 117: e1049-e1056 [Abstract] [Full Text]  
• Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Offord, J. R., Dispenzieri, A., Katzmann, J. A., Melton, L. J. III (2006). Prevalence of monoclonal gammopathy of undetermined significance.. NEJM 354: 1362-1369 [Abstract] [Full Text]  
• Garton, M. J., Keir, G., Dickie, A., Steven, M., Rennie, J. A. N. (2006). Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis. Rheumatology (Oxford) 45: 355-356 [Full Text]  
• Landgren, O., Gridley, G., Turesson, I., Caporaso, N. E., Goldin, L. R., Baris, D., Fears, T. R., Hoover, R. N., Linet, M. S. (2006). Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood 107: 904-906 [Abstract] [Full Text]  
• Chng, W. J., Van Wier, S. A., Ahmann, G. J., Winkler, J. M., Jalal, S. M., Bergsagel, P. L., Chesi, M., Trendle, M. C., Oken, M. M., Blood, E., Henderson, K., Santana-Davila, R., Kyle, R. A., Gertz, M. A., Lacy, M. Q., Dispenzieri, A., Greipp, P. R., Fonseca, R. (2005). A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 106: 2156-2161 [Abstract] [Full Text]  
• Bergsagel, P. L., Kuehl, W. M. (2005). Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma. JCO 23: 6333-6338 [Abstract] [Full Text]  
• Kumar, S., Rajkumar, S. V., Kyle, R. A., Lacy, M. Q., Dispenzieri, A., Fonseca, R., Lust, J. A., Gertz, M. A., Greipp, P. R., Witzig, T. E. (2005). Prognostic Value of Circulating Plasma Cells in Monoclonal Gammopathy of Undetermined Significance. JCO 23: 5668-5674 [Abstract] [Full Text]  
• Munshi, N. C. (2005). Determining the undetermined. Blood 106: 767-768 [Full Text]  
• Rajkumar, S. V., Kyle, R. A., Therneau, T. M., Melton, L. J. III, Bradwell, A. R., Clark, R. J., Larson, D. R., Plevak, M. F., Dispenzieri, A., Katzmann, J. A. (2005). Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106: 812-817 [Abstract] [Full Text]  
• Baldini, L., Goldaniga, M., Guffanti, A., Broglia, C., Cortelazzo, S., Rossi, A., Morra, E., Colombi, M., Callea, V., Pogliani, E., Ilariucci, F., Luminari, S., Morel, P., Merlini, G., Gobbi, P. (2005). Immunoglobulin M Monoclonal Gammopathies of Undetermined Significance and Indolent Waldenstrom's Macroglobulinemia Recognize the Same Determinants of Evolution Into Symptomatic Lymphoid Disorders: Proposal for a Common Prognostic Scoring System. JCO 23: 4662-4668 [Abstract] [Full Text]  
• Jungbluth, A. A., Ely, S., DiLiberto, M., Niesvizky, R., Williamson, B., Frosina, D., Chen, Y.-T., Bhardwaj, N., Chen-Kiang, S., Old, L. J., Cho, H. J. (2005). The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106: 167-174 [Abstract] [Full Text]  
• Eurelings, M., Lokhorst, H. M., Kalmijn, S., Wokke, J.H.J., Notermans, N. C. (2005). Malignant transformation in polyneuropathy associated with monoclonal gammopathy. Neurology 64: 2079-2084 [Abstract] [Full Text]  
• Gniadecki, R., Lukowsky, A. (2005). Monoclonal T-Cell Dyscrasia of Undetermined Significance Associated With Recalcitrant Erythroderma. Arch Dermatol 141: 361-367 [Abstract] [Full Text]  
• Abraham, R. S., Ballman, K. V., Dispenzieri, A., Grill, D. E., Manske, M. K., Price-Troska, T. L., Paz, N. G., Gertz, M. A., Fonseca, R. (2005). Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 105: 794-803 [Abstract] [Full Text]  
• Rajkumar, S. V. (2005). MGUS and Smoldering Multiple Myeloma: Update on Pathogenesis, Natural History, and Management. ASH Education Book 2005: 340-345 [Abstract] [Full Text]  
• Kuehl, W. M., Bergsagel, P. L. (2005). Early Genetic Events Provide the Basis for a Clinical Classification of Multiple Myeloma. ASH Education Book 2005: 346-352 [Abstract] [Full Text]  
• Kyle, R. A., Rajkumar, S. V. (2004). Multiple Myeloma. NEJM 351: 1860-1873 [Full Text]  
• Sallah, S., Husain, A., Wan, J., Vos, P., Nguyen, N. P. (2004). The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Ann Oncol 15: 1490-1494 [Abstract] [Full Text]  
• Velangi, M. R., Matheson, E. C., Morgan, G. J., Jackson, G. H., Taylor, P. R., Hall, A. G., Irving, J. A.E. (2004). DNA mismatch repair pathway defects in the pathogenesis and evolution of myeloma. Carcinogenesis 25: 1795-1803 [Abstract] [Full Text]  
• Morris, M. C., Nadkarni, V. M., Ward, F. R., Nelson, R. M. (2004). Exception From Informed Consent for Pediatric Resuscitation Research: Community Consultation for a Trial of Brain Cooling After In-Hospital Cardiac Arrest. Pediatrics 114: 776-781 [Abstract] [Full Text]  
• Hideshima, T., Bergsagel, P. L., Kuehl, W. M., Anderson, K. C. (2004). Advances in biology of multiple myeloma: clinical applications. Blood 104: 607-618 [Abstract] [Full Text]  
• Blade, J. (2004). On the "Significance" of Monoclonal Gammopathy of Undetermined Significance. Mayo Clin Proc. 79: 855-856  
• Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Larson, D. R., Plevak, M. F., Melton, L. J. III (2004). Long-term Follow-up of 241 Patients With Monoclonal Gammopathy of Undetermined Significance: The Original Mayo Clinic Series 25 Years Later. Mayo Clin Proc. 79: 859-866 [Abstract]  
• Ma, C. X., Lacy, M. Q., Rompala, J. F., Dispenzieri, A., Rajkumar, S. V., Greipp, P. R., Fonseca, R., Kyle, R. A., Gertz, M. A. (2004). Acquired Fanconi syndrome is an indolent disorder in the absence of overt multiple myeloma. Blood 104: 40-42 [Abstract] [Full Text]  
• Chim, C.-S., Fung, T.-K., Cheung, W.-C., Liang, R., Kwong, Y.-L. (2004). SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway. Blood 103: 4630-4635 [Abstract] [Full Text]  
• Takahashi, T., Shivapurkar, N., Reddy, J., Shigematsu, H., Miyajima, K., Suzuki, M., Toyooka, S., Zochbauer-Muller, S., Drach, J., Parikh, G., Zheng, Y., Feng, Z., Kroft, S. H., Timmons, C., McKenna, R. W., Gazdar, A. F. (2004). DNA Methylation Profiles of Lymphoid and Hematopoietic Malignancies. Clin. Cancer Res. 10: 2928-2935 [Abstract] [Full Text]  
• Angtuaco, E. J. C., Fassas, A. B. T., Walker, R., Sethi, R., Barlogie, B. (2004). Multiple Myeloma: Clinical Review and Diagnostic Imaging. Radiology 231: 11-23 [Abstract] [Full Text]  
• Ghia, P., Prato, G., Scielzo, C., Stella, S., Geuna, M., Guida, G., Caligaris-Cappio, F. (2004). Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly. Blood 103: 2337-2342 [Abstract] [Full Text]  
• Kleta, R., Blair, S. C., Bernardini, I., Kaiser-Kupfer, M. I., Gahl, W. A. (2004). Keratopathy of Multiple Myeloma Masquerading as Corneal Crystals of Ocular Cystinosis. Mayo Clin Proc. 79: 410-412 [Abstract]  
• Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P. L., Chesi, M., Davies, F. E., Drach, J., Greipp, P. R., Kirsch, I. R., Kuehl, W. M., Hernandez, J. M., Minvielle, S., Pilarski, L. M., Shaughnessy, J. D. Jr., Stewart, A. K., Avet-Loiseau, H. (2004). Genetics and Cytogenetics of Multiple Myeloma: A Workshop Report. Cancer Res. 64: 1546-1558 [Abstract] [Full Text]  
• Harousseau, J.-L., Shaughnessy, J. Jr., Richardson, P. (2004). Multiple Myeloma. ASH Education Book 2004: 237-256 [Abstract] [Full Text]  
• Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R., Crowley, J. (2004). Treatment of multiple myeloma. Blood 103: 20-32 [Abstract] [Full Text]  
• Davies, F. E., Dring, A. M., Li, C., Rawstron, A. C., Shammas, M. A., O'Connor, S. M., Fenton, J. A.L., Hideshima, T., Chauhan, D., Tai, I. T., Robinson, E., Auclair, D., Rees, K., Gonzalez, D., Ashcroft, A. J., Dasgupta, R., Mitsiades, C., Mitsiades, N., Chen, L. B., Wong, W. H., Munshi, N. C., Morgan, G. J., Anderson, K. C. (2003). Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood 102: 4504-4511 [Abstract] [Full Text]  
• Dhodapkar, M. V., Krasovsky, J., Osman, K., Geller, M. D. (2003). Vigorous Premalignancy-specific Effector T Cell Response in the Bone Marrow of Patients with Monoclonal Gammopathy. JEM 198: 1753-1757 [Abstract] [Full Text]  
• Finn, O. J. (2003). Premalignant Lesions as Targets for Cancer Vaccines. JEM 198: 1623-1626 [Full Text]  
• Kyle, R. A., Therneau, T. M., Rajkumar, S. V., Remstein, E. D., Offord, J. R., Larson, D. R., Plevak, M. F., Melton, L. J. III (2003). Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 102: 3759-3764 [Abstract] [Full Text]  
• Lu, C. M., Dezube, B. J., Pantanowitz, L. (2003). HIV Infection Masquerading as Monoclonal Gammopathy of Undetermined Significance. NEJM 349: 1192-1193 [Full Text]  
• Shaughnessy, J. Jr (2003). Primer on Medical Genomics Part IX: Scientific and Clinical Applications of DNA Microarrays--Multiple Myeloma as a Disease Model. Mayo Clin Proc. 78: 1098-1109 [Abstract]  
• Tate, J. R., Gill, D., Cobcroft, R., Hickman, P. E. (2003). Practical Considerations for the Measurement of Free Light Chains in Serum. Clin. Chem. 49: 1252-1257 [Abstract] [Full Text]  
• Strobel, S. L. (2003). Transient Paraproteinemia: An Intriguing Immunological Anomaly. Annals of Clinical & Laboratory Science 33: 265-270 [Abstract] [Full Text]  
• Zojer, N., Ludwig, H., Fiegl, M., Stevenson, F. K., Sahota, S. S. (2003). Patterns of somatic mutations in VH genes reveal pathways of clonal transformation from MGUS to multiple myeloma. Blood 101: 4137-4139 [Abstract] [Full Text]  
• Barille-Nion, S., Barlogie, B., Bataille, R., Bergsagel, P. L., Epstein, J., Fenton, R. G., Jacobson, J., Kuehl, W. M., Shaughnessy, J., Tricot, G. (2003). Advances in Biology and Therapy of Multiple Myeloma. ASH Education Book 2003: 248-278 [Abstract] [Full Text]  
• Anderson, K. C. (2003). Multiple Myeloma: How Far Have We Come?. Mayo Clin Proc. 78: 15-17  
• Durie, B. G.M., Waxman, A. D., D'Agnolo, A., Williams, C. M. (2002). Whole-Body 18F-FDG PET Identifies High-Risk Myeloma. JNM 43: 1457-1463 [Abstract] [Full Text]  
• Rawstron, A. C., Yuille, M. R., Fuller, J., Cullen, M., Kennedy, B., Richards, S. J., Jack, A. S., Matutes, E., Catovsky, D., Hillmen, P., Houlston, R. S. (2002). Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood 100: 2289-2290 [Abstract] [Full Text]